Spyre Therapeutics, Inc.
SYRE NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Aug 4, 2026
ET
EPS Est.
-0.76
EPS Actual
-0.36
Revenue Est.
--
Revenue Actual
--
Next Earnings Report
Date
Nov 3, 2026 · Tue
Time
Time TBD
Fiscal Period
FY2026 Q3
EPS Est.
-0.80
Revenue Est.
--
Company Overview
Spyre Therapeutics, Inc. (ticker SYRE) is listed on NASDAQ with a market cap of about $9.25B. Its next earnings report (FY2026 Q3) is expected on Nov 3, 2026 (ET), Time TBD, with consensus EPS of -0.80. In the last 15 reported quarters, EPS beat consensus estimates 7 times.
Actual EPS TrendRecently15Term · Mar 2, 2023 → Aug 4, 2026
Mar 2, 2023Range: -9.34 ~ -0.15Aug 4, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 4, 2026 | -- | -0.76 | Above forecast↑-0.36 | -- | -- |
| May 5, 2026 | -- | -0.66 | -0.74 | -- | -- |
| Feb 19, 2026 | -- | -0.66 | -0.70 | $142.9M | $90.5M |
| Nov 4, 2025 | -- | -0.76 | Above forecast↑-0.15 | $2M | -- |
| Aug 5, 2025 | -- | -0.73 | Above forecast↑-0.49 | -- | -- |
| May 8, 2025 | -- | -0.84 | -0.74 | $4M | -- |
| Feb 28, 2025 | -- | -0.89 | -0.81 | $3M | -- |
| Nov 7, 2024 | -- | -0.80 | Below forecast↓-1.36 | $2.6M | -- |
| Aug 7, 2024 | -- | -0.90 | -0.86 | $6.7M | -- |
| May 9, 2024 | -- | -0.90 | Below forecast↓-1.20 | -- | -- |
| Feb 29, 2024 | -- | -0.48 | Below forecast↓-4.05 | $371333 | -- |
| Nov 9, 2023 | -- | -0.84 | Below forecast↓-9.34 | $198000 | -- |
| Aug 11, 2023 | -- | -0.03 | Below forecast↓-0.57 | $198000 | $688000 |
| May 11, 2023 | -- | -4.50 | -5.00 | $184000 | $198000 |
| Mar 2, 2023 | -- | -5.71 | -5.00 | $133333 | $168000 |
Original Filings (SEC)
8-K2026-08-04 ↗
10-Q2026-08-04 ↗
8-K2026-06-15 ↗
8-K2026-06-01 ↗
8-K2026-05-29 ↗
8-K2026-05-05 ↗
10-Q2026-05-05 ↗
8-K2026-04-16 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
